Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD19 chimeric antigen receptor T cell therapy - Sheba Medical Center

Next Previous
X
Search
Drug Profile

Anti CD19 chimeric antigen receptor T cell therapy - Sheba Medical Center

Alternative Names: Anti-CD19 CAR-T Cell Therapy - Sheba Medical Center; CD19 CAR-T cell immunotherapy - Sheba Medical Center

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sheba Medical Center
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 08 Jun 2023 Adverse events data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 05 Dec 2020 Updated efficacy and adverse events data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Haematology (ASH-2020)
  • 25 Dec 2019 Efficacy and adverse events data from a phase I/II trial in B-cell lymphoblastic leukaemia-lymphoma released by Sheba Medical Center

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top